Lopez LM, Grimes DA, Schulz KF: Steroidal contraceptives: efect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database SYSt Rev 2:CD006133, 2014
Lopez LM, Kaptein A, Helmerhorst FM: Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2:CD006586,n2012b
Luan NN, Wu L, Gong TT, et al: Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes Control 26(1):65, 2015
MacClellan LR, Giles W, Cole ], et al: Probable migraine with visual aura and risk of ischemic stroke: the Stroke Prevention in Young Women Study. Stroke 38:2438, 2007
Madden T, McNicholas C, Zhao Q, et al: Association of age and pariry with intrauterine device expulsion. Obstet Gynecol 124(4):718,n2014
Madden T, Proehl S, AIlsworth JE, et al: Naproxen or estradiol for bleeding and spotting with the levonorgestrel intraurerine system: a randomized controlled trial. Am] Obstet GynecoI206(2):129.e1, 2012
Maheshwari S, Sarraj A, Kramer ], et al: Oral contraception and the risk of hepatocellular carcinoma. ] Hepatol 47:506, 2007
Mansour 0, Gemzell-Danielsson K, Inki P, et al: Fertiliry after discontinuation of contraception: a comprehensive review of the literature. Contraception 84(5):465,n2011
Mantha S, Karp R, Raghavan V, et al: Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BM] 345:e4944, 2012
Marchbanks PA, McDonald]A, Wilson HG, et al: Oral contraceptives and the risk of breast cancer. N Engl] Med 346(26):2025, 2002
Margolis KL, Adami HO, Luo], et al: A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Ferril Steril 88:310, 2007
Marr ], Gerlinger C, Kunz M: A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinyl estradiol 30 flg/drospirenone 3 mg administered in a 2117 regimen versus ethinyl estradiol 20 pg/drospirenone 3 mg administered in a 24/4 regimen. Eurn] Obstet Gynecol Reprod Bioi 162(1):91, 2012
Mauck C, Callahan M, Weiner DH, et al: A comparative study of the safety and eicacy of FemCap, a new vaginal barrier contraceptive, and the Orrho AIIFlex diaphragm. he FemCap Investigators' Group. Contraception 60(2): 1, 1999
Mendoza N, Lobo P, Lertxundi R, et al: Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies. Eur] Contracept Reprod Health Care 19(5):321,n2014